The Meals and Drug Administration has lastly accredited Novavax’s Covid-19 vaccine, however in doing so has positioned restrictions on it that its two rivals within the U.S. market don’t face.
The long-awaited license limits use of the vaccine to individuals 65 and older and other people aged 12 to 64 who’ve no less than one medical situation that places them at greater danger of extreme sickness in the event that they contract Covid. The vaccine has been obtainable beneath an emergency use authorization.
The FDA missed an April 1 deadline to rule on Novavax’s software. It was reported that political appointees in Commissioner Marty Makary’s workplace overrode profession workers, who advisable issuing the license. Novavax’s inventory value is down 21% for the reason that begin of the 12 months.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
